As we prepare to expand Principia's research and operations, we agreed that this would be an ideal time to seize the opportunity to bring our teams together geographically and achieve the seamless operations crucial to our long-term success. We believe this relocation will enhance research and operating synergy and productivity. The employees who move will be assisted with relocation benefits packages. Principia's recombinant albumin fusion technology is intended to provide longer acting forms of many important biopharmaceuticals by genetically fusing the therapeutic protein to albumin.
Albumin is a very abundant long-lived natural protein in the blood.
When fused to therapeutically active proteins, the active proteins are anticipated to have the long circulating life of albumin. This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the company's unproven business model, dependence on new technologies, uncertainty as to clinical trial results, ability to develop and commercialize products, dependence on collaborators for services and revenue, substantial indebtedness, intense competition, uncertainty of patent and intellectual property protection, dependence on key management, uncertainty of regulation of products, dependence on key suppliers and other risks that may be described in the company's filings with the Securities and Exchange Commission.